| 產(chǎn)品編號 | BIO0999SM |
| 英文名稱 | Anti-HER2/neu Reference Antibody (Zanidatamab Biosimilar) |
| 別 名 | ERBB2 / HER2 / CD340; Zanidatamab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 124.81kDa |
| 性 狀 | Lyophilized |
| 亞 型 | Half IgG+ScFv |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Zanidatamab with BT474 cell and PBMCs for 4 hours, then LDH was detected to evaluate the ADCC activity of Zanidatamab. As shown in fig, Zanidatamab has ADCC activity, and the IC50 was 0.023 nM.
Zanidatamab bound to BT474 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Zanidatamab bound to BT474 cells, and the EC50 was 3.061 nM.
Zanidatamab bound to HER2 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Zanidatamab bound to hu-HER2-his, and the EC50 was 0.012 nM.
The purity of Anti-HER2/neu Reference Antibody (Zanidatamab) is 98.25%, determined by SEC-HPLC.
Anti-HER2/neu Reference Antibody (Zanidatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-HER2/neu Reference Antibody (Zanidatamab) is 124.82 kDa.
|
